Mind the Gap! Closing the Fusion Divide With Evidence-Based Orthobiologics

Thursday, April 20th, 2017 | 11:00am - 12:00pm CT

At a time when therapeutic decisions are based on reasoned burdens of proof, there is strikingly little evidence supporting the use of most bone graft products. Despite a market that boasts over 300 options, only two have satisfied the highest regulatory requirements for use in spinal fusion and had their Level I data go into publication. With commercial insurers and CMS demanding evidence in support of coverage decisions, your choice in bone grafting material could impact your bottom line.

Attendees will be able to:

  • Assess bone grafting options based on the evidence that supports them
  • Separate fact from fiction in terms of regulatory scrutiny and payer mandated evidence
  • Learn from a surgeon, active in research and teaching, why diving deep into the science and data helps his practice and patients
  • Better understand how an advanced biologic, i-FACTOR Peptide Enhanced Bone Graft, has redefined the category

 Michael E Janssen, DO - Founder - Center for Spine and Orthopedics.png